EU/3/01/022

Table of contents

About

Please note that this product was withdrawn from the Community register of designated orphan medicinal products in June 2013 at the end of the period of market exclusivity.

On 14 February 2001, orphan designation (EU/3/01/022) was granted by the European Commission to Genzyme BV, the Netherlands, for Laronidase for the treatment of mucopolysaccharidosis, type I.

The sponsor changed name to Genzyme Europe BV in 2002.

Laronidase has been authorised in the EU as Aldurazyme since 10 June 2003.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
laronidase
Medicine name
Aldurazyme
Disease / condition
Treatment of mucopolysaccharidosis type I
Date of first decision
15/02/2001
Outcome
Expired
EU designation number
EU/3/01/022

Sponsor's contact details

Genzyme Europe BV
Gooimeer 10
1411 DD Naarden
The Netherlands
Tel. +31 35 699 1200
Fax +31 35 694 3214
E-mail: eumedinfo@genzyme.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating